D-0575-2023 Class II Ongoing

Recalled by Sanofi-Aventis U.S. LLC — Bridgewater, NJ

FDA drug recall D-0575-2023 was initiated by Sanofi-Aventis U.S. LLC on Apr 11, 2023 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: Malformed crimped collar seal The recall status is ongoing. Affected quantity: 51,325 vials.

Recall details

Product Type
Drugs
Report Date
May 24, 2023
Initiation Date
Apr 11, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
51,325 vials

Product description

Admelog, insulin lispro injection, 100 units/mL (U-100), 3mL multi-dose vial, Rx Only, Sanofi-Aventis U.S. LLC, Bridgewater, NJ 08807 A Sanofi Company. NDC 0024-5926-05

Reason for recall

Lack of Assurance of Sterility: Malformed crimped collar seal

Distribution pattern

Nationwide in the USA

Code information

Lot # 3F497B, EXP 12-31-2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0575-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0575-2023. Report a data issue: hello@regdatalab.com.